Jessica D Kondraciuk1, Samuel L Rice2, Xiaosun Zhou1, Karem Gharzeddine1, Andrea Knezevic3, Daniel E Spratt4, Mona Sabra5, Steven M Larson1,6,7,8, Ravinder K Grewal1,8, Joseph R Osborne8. 1. From the Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Radiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center. 6. Molecular Pharmacology Program, Sloan Kettering Institute. 7. Center for Targeted Radioimmunotherapy and Theranostics, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center. 8. Department of Radiology, Weill Medical College of Cornell University, New York, NY.
Abstract
Bone metastasis (BM) in differentiated thyroid cancer (DTC) is the second most common site of metastasis after lung. Bone metastases are associated with worse prognosis in DTC. In this study, we examined risk factors for overall survival in patients with BM and for the first time explore the pattern of genomic alterations in DTC BM. PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act (HIPAA) compliant, institutional review board-approved retrospective evaluation of the medical record was performed for all patients treated at a single institution for thyroid cancer over a 16-year period. Seventy-four patients met inclusion criteria. Multiple prognostic factors including age, sex, genes, radioactive iodine, and radiation or kinase inhibitor therapies were analyzed. Univariate and multivariate analyses were performed. RESULTS: Treatment with external beam radiation was found to significantly increase survival (P = 0.03). The 5-year survival rate was 59% and median survival was 92 months. Patients who developed bone metastasis earlier tend to live longer (P = 0.06). The presence of TERT and BRAF mutations did not significantly worsen the prognosis (P = 0.10). CONCLUSION: Patients with DTC can benefit from early treatment with external beam radiation therapy, especially those who develop bone metastasis within 3 years of primary TC diagnosis. Kinase inhibitor treatment tended to prolong survival but not in a statistically significant manner. Sex, age, and TERT or BRAF genetic mutations did not significantly affect the prognosis.
Bone metastasis (BM) in differentiated thyroid cancer (DTC) is the second most common site of metastasis after lung. Bone metastases are associated with worse prognosis in DTC. In this study, we examined risk factors for overall survival in patients with BM and for the first time explore the pattern of genomic alterations in DTC BM. PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act (HIPAA) compliant, institutional review board-approved retrospective evaluation of the medical record was performed for all patients treated at a single institution for thyroid cancer over a 16-year period. Seventy-four patients met inclusion criteria. Multiple prognostic factors including age, sex, genes, radioactive iodine, and radiation or kinase inhibitor therapies were analyzed. Univariate and multivariate analyses were performed. RESULTS: Treatment with external beam radiation was found to significantly increase survival (P = 0.03). The 5-year survival rate was 59% and median survival was 92 months. Patients who developed bone metastasis earlier tend to live longer (P = 0.06). The presence of TERT and BRAF mutations did not significantly worsen the prognosis (P = 0.10). CONCLUSION:Patients with DTC can benefit from early treatment with external beam radiation therapy, especially those who develop bone metastasis within 3 years of primary TC diagnosis. Kinase inhibitor treatment tended to prolong survival but not in a statistically significant manner. Sex, age, and TERT or BRAF genetic mutations did not significantly affect the prognosis.
Authors: Richard J Robbins; Qiang Wan; Ravinder K Grewal; Roland Reibke; Mithat Gonen; H William Strauss; R Michael Tuttle; William Drucker; Steven M Larson Journal: J Clin Endocrinol Metab Date: 2005-11-22 Impact factor: 5.958
Authors: C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2006-05-09 Impact factor: 5.958
Authors: Georg Zettinig; Barbara J Fueger; Christian Passler; Klaus Kaserer; Christian Pirich; Robert Dudczak; Bruno Niederle Journal: Clin Endocrinol (Oxf) Date: 2002-03 Impact factor: 3.478
Authors: Hendrieke Hoftijzer; Karen A Heemstra; Hans Morreau; Marcel P Stokkel; Eleonora P Corssmit; Hans Gelderblom; Karin Weijers; Alberto M Pereira; Maya Huijberts; Ellen Kapiteijn; Johannes A Romijn; Johannes W Smit Journal: Eur J Endocrinol Date: 2009-09-22 Impact factor: 6.664
Authors: M M Muresan; P Olivier; J Leclère; F Sirveaux; L Brunaud; M Klein; R Zarnegar; G Weryha Journal: Endocr Relat Cancer Date: 2008-03 Impact factor: 5.678
Authors: Brian Hung-Hin Lang; Kai Pun Wong; Chung Yeung Cheung; Koon Yat Wan; Chung-Yau Lo Journal: Ann Surg Oncol Date: 2012-10-28 Impact factor: 5.344
Authors: Arnaud Jannin; Livia Lamartina; Coralie Moutarde; Mehdi Djennaoui; George Lion; Benjamin Chevalier; Marie Christine Vantyghem; Frédéric Deschamps; Julien Hadoux; Eric Baudin; Martin Schlumberger; Sophie Leboulleux; Christine Do Cao Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-12 Impact factor: 10.057
Authors: Shiga Rappai Chirayath; Usha V Menon; Vasantha Nair; Harish Kumar; V P Praveen; Nisha Bhavani; Nithya Abraham Journal: Indian J Endocrinol Metab Date: 2022-08-04